Tumor-cell PD-L1 expression, mismatch repair status, and survival outcomes in colorectal carcinoma: a retrospective Pakistani cohort study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Assessment of PD-L1 Expression, Mismatch Repair Status, and Survival Rates in Colorectal Cancer: A Retrospective Study from Pakistan

  • By

  • Kanza Atif

  • Aiman Ajmeer

  • Abdal Ahmad

  • Fozia Rauf

  • Umer Khan

  • Sarah Yousuf

  • Bilal Ahmad

  • Sadia Qazi

  • September 14, 2026

Share

  • 1

    The study evaluated PD-L1 expression in colorectal cancer using the ZR3 clone in a cohort of 60 patients from Pakistan.

  • 2

    PD-L1 expression was detected in 71.7% of tumors, with 31 low-positive and 12 high-positive cases, reflecting assay-specific behavior.

  • 3

    MSI-H/dMMR status was found in 20% of tumors and correlated with high PD-L1 expression, but no association was observed with binary PD-L1 positivity.

  • 4

    PD-L1 status showed no relationship with overall survival, disease-free survival, or progression-free survival in the studied cohort.

  • 5

    The study concluded that PD-L1 TPS should remain a research measure, while MSI/MMR testing is the clinically actionable biomarker for CRC.

Original Source(s)

Tumor-cell PD-L1 expression, mismatch repair status, and survival outcomes in colorectal carcinoma: a retrospective Pakistani cohort study

  • by Kanza Atif, Aiman Ajmeer, Abdal Ahmad, Fozia Rauf, Umer Khan, Sarah Yousuf, Bilal Ahmad, Sadia Qazi

  • September 14, 2026

Related Content

Matters arising in IJCD beyond minimally invasive pelvic exenteration: can single-port robotics overcome deep pelvic constraints?

Retraction Note: Atovaquone inhibits colorectal cancer metastasis by regulating PDGFRβ/NF-κB signaling pathway

Machine learning to develop and validate a model for predicting the risk of lymph node metastasis in colorectal cancer patients